Brolucizumab

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 568 publications

Comparison of Intraocular Inflammation Associated with High-Dose Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Real-World Disproportionality Analysis.

Comparison of Intraocular Inflammation Associated with High-Dose Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Real-World Disproportionality Analysis.

Journal: Ocular immunology and inflammation

Published: June 01, 2026

Cost analysis of aflibercept 8 mg versus other anti-VEGF agents

Cost analysis of aflibercept 8 mg versus other anti-VEGF agents

Journal: Vestnik oftalmologii

Published: April 28, 2026

Antiangiogenic therapy after cataract surgery in neovascular age-related macular degeneration (clinical observation)

Antiangiogenic therapy after cataract surgery in neovascular age-related macular degeneration (clinical observation)

Journal: Vestnik oftalmologii

Published: April 28, 2026

Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial.

Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial.

Journal: JAMA ophthalmology

Published: April 23, 2026

Signals of Drug-Related Retinal Fibrosis: Findings From a 20-Year Disproportionality Analysis of Global Spontaneous Reports.

Signals of Drug-Related Retinal Fibrosis: Findings From a 20-Year Disproportionality Analysis of Global Spontaneous Reports.

Journal: Translational vision science & technology

Published: April 13, 2026

Efficacy and Safety of Anti-vascular Endothelial Growth Factor (VEGF) Agents in Diabetic Macular Edema.

Efficacy and Safety of Anti-vascular Endothelial Growth Factor (VEGF) Agents in Diabetic Macular Edema.

Journal: Cureus

Published: March 19, 2026

Real-World Experience with Brolucizumab in Treatment-Naïve nAMD with Low Baseline Visual Acuity: Short-Term Outcomes from a Prospective Single-Institution Study.

Real-World Experience with Brolucizumab in Treatment-Naïve nAMD with Low Baseline Visual Acuity: Short-Term Outcomes from a Prospective Single-Institution Study.

Journal: Life (Basel, Switzerland)

Published: March 14, 2026

Systemic and ocular complications related to intravitreal administration of anti-VEGF agents.

Systemic and ocular complications related to intravitreal administration of anti-VEGF agents.

Journal: Medical hypothesis, discovery & innovation ophthalmology journal

Published: March 06, 2026

Results from a French brolucizumab access program for pretreated patients with neovascular age-related macular degeneration.

Results from a French brolucizumab access program for pretreated patients with neovascular age-related macular degeneration.

Journal: European journal of ophthalmology

Published: March 05, 2026

Intravitreal Brolucizumab Use for Retinal Vascular Diseases in Resource-Constrained Settings: A Retrospective Study From Bangladesh.

Intravitreal Brolucizumab Use for Retinal Vascular Diseases in Resource-Constrained Settings: A Retrospective Study From Bangladesh.

Journal: Cureus

Published: February 08, 2026

Peep into anti-vascular endothelial growth factor.

Peep into anti-vascular endothelial growth factor.

Journal: Indian journal of ophthalmology

Published: February 07, 2026

Aflibercept and Brolucizumab in Diabetic Macular Edema: A Focused Review of Efficacy, Safety, and Clinical Considerations.

Aflibercept and Brolucizumab in Diabetic Macular Edema: A Focused Review of Efficacy, Safety, and Clinical Considerations.

Journal: Biomedicines

Published: January 31, 2026

Showing 1-12 of 568

Last Updated: 06/30/2026